MX2023003054A - Formas solidas de un inhibidor de cdk4. - Google Patents
Formas solidas de un inhibidor de cdk4.Info
- Publication number
- MX2023003054A MX2023003054A MX2023003054A MX2023003054A MX2023003054A MX 2023003054 A MX2023003054 A MX 2023003054A MX 2023003054 A MX2023003054 A MX 2023003054A MX 2023003054 A MX2023003054 A MX 2023003054A MX 2023003054 A MX2023003054 A MX 2023003054A
- Authority
- MX
- Mexico
- Prior art keywords
- solid forms
- cdk4 inhibitor
- pharmaceutical compositions
- forms
- cdk4
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 3
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078636P | 2020-09-15 | 2020-09-15 | |
| US202163240268P | 2021-09-02 | 2021-09-02 | |
| PCT/IB2021/058320 WO2022058871A1 (en) | 2020-09-15 | 2021-09-13 | Solid forms of a cdk4 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003054A true MX2023003054A (es) | 2023-04-05 |
Family
ID=78000744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003054A MX2023003054A (es) | 2020-09-15 | 2021-09-13 | Formas solidas de un inhibidor de cdk4. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230357211A1 (enExample) |
| EP (2) | EP4214202B1 (enExample) |
| JP (2) | JP7260606B2 (enExample) |
| KR (1) | KR20230069983A (enExample) |
| CN (1) | CN116507620B (enExample) |
| AU (1) | AU2021345531B2 (enExample) |
| CA (1) | CA3195063A1 (enExample) |
| DK (1) | DK4214202T3 (enExample) |
| ES (1) | ES3022913T3 (enExample) |
| FI (1) | FI4214202T3 (enExample) |
| HU (1) | HUE070846T2 (enExample) |
| MX (1) | MX2023003054A (enExample) |
| PL (1) | PL4214202T3 (enExample) |
| PT (1) | PT4214202T (enExample) |
| SI (1) | SI4214202T1 (enExample) |
| TW (2) | TW202334125A (enExample) |
| WO (1) | WO2022058871A1 (enExample) |
| ZA (1) | ZA202303655B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022002415A (es) | 2019-08-26 | 2022-03-22 | Arvinas Operations Inc | Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos. |
| EP4440576A1 (en) * | 2021-12-02 | 2024-10-09 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| JP2025533719A (ja) | 2022-07-29 | 2025-10-09 | ファイザー・インク | がんの治療のためのｋａｔ６阻害剤を含む投与レジメン |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| KR20250164842A (ko) | 2023-03-30 | 2025-11-25 | 화이자 인코포레이티드 | Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법 |
| WO2024246825A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Combinations of estrogen receptor degraders and cdk4 inhibitors |
| WO2024246824A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| US12338248B2 (en) | 2023-07-21 | 2025-06-24 | Accutar Biotechnology Inc. | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
| WO2025104624A1 (en) | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
| WO2025202871A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2025202900A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| CN110036004A (zh) * | 2016-07-13 | 2019-07-19 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| MA45920B1 (fr) | 2016-08-15 | 2021-08-31 | Pfizer | Inhibiteurs de pyridopyrimidinone cdk2/4/6 |
| CA3098283C (en) * | 2018-04-26 | 2023-05-23 | Pfizer Inc. | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
-
2021
- 2021-09-13 DK DK21783049.6T patent/DK4214202T3/da active
- 2021-09-13 JP JP2021148619A patent/JP7260606B2/ja active Active
- 2021-09-13 US US18/245,039 patent/US20230357211A1/en active Pending
- 2021-09-13 KR KR1020237012766A patent/KR20230069983A/ko not_active Ceased
- 2021-09-13 SI SI202130288T patent/SI4214202T1/sl unknown
- 2021-09-13 WO PCT/IB2021/058320 patent/WO2022058871A1/en not_active Ceased
- 2021-09-13 HU HUE21783049A patent/HUE070846T2/hu unknown
- 2021-09-13 MX MX2023003054A patent/MX2023003054A/es unknown
- 2021-09-13 PL PL21783049.6T patent/PL4214202T3/pl unknown
- 2021-09-13 FI FIEP21783049.6T patent/FI4214202T3/fi active
- 2021-09-13 EP EP21783049.6A patent/EP4214202B1/en active Active
- 2021-09-13 ES ES21783049T patent/ES3022913T3/es active Active
- 2021-09-13 CN CN202180071477.7A patent/CN116507620B/zh active Active
- 2021-09-13 PT PT217830496T patent/PT4214202T/pt unknown
- 2021-09-13 CA CA3195063A patent/CA3195063A1/en active Pending
- 2021-09-13 AU AU2021345531A patent/AU2021345531B2/en active Active
- 2021-09-13 EP EP25153633.0A patent/EP4578450A3/en active Pending
- 2021-09-14 TW TW112102545A patent/TW202334125A/zh unknown
- 2021-09-14 TW TW110134168A patent/TWI809503B/zh active
-
2022
- 2022-10-27 JP JP2022172594A patent/JP7291839B2/ja active Active
-
2023
- 2023-03-16 ZA ZA2023/03655A patent/ZA202303655B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202303655B (en) | 2024-09-25 |
| EP4578450A2 (en) | 2025-07-02 |
| JP2022049005A (ja) | 2022-03-28 |
| HUE070846T2 (hu) | 2025-07-28 |
| TW202216698A (zh) | 2022-05-01 |
| BR112023004713A2 (pt) | 2023-04-18 |
| SI4214202T1 (sl) | 2025-05-30 |
| CA3195063A1 (en) | 2022-03-24 |
| PT4214202T (pt) | 2025-04-11 |
| AU2021345531B2 (en) | 2024-02-29 |
| JP7291839B2 (ja) | 2023-06-15 |
| EP4578450A3 (en) | 2025-07-16 |
| US20230357211A1 (en) | 2023-11-09 |
| EP4214202A1 (en) | 2023-07-26 |
| TWI809503B (zh) | 2023-07-21 |
| EP4214202B1 (en) | 2025-02-26 |
| KR20230069983A (ko) | 2023-05-19 |
| WO2022058871A1 (en) | 2022-03-24 |
| PL4214202T3 (pl) | 2025-05-19 |
| ES3022913T3 (en) | 2025-05-29 |
| FI4214202T3 (fi) | 2025-04-25 |
| TW202334125A (zh) | 2023-09-01 |
| CN116507620B (zh) | 2025-11-18 |
| JP2022186995A (ja) | 2022-12-15 |
| CN116507620A (zh) | 2023-07-28 |
| DK4214202T3 (da) | 2025-03-31 |
| AU2021345531A1 (en) | 2023-04-20 |
| JP7260606B2 (ja) | 2023-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003054A (es) | Formas solidas de un inhibidor de cdk4. | |
| UA100846C2 (uk) | Сполуки та композиція як інгібітори протеїнкінази | |
| MX2010002258A (es) | Compuestos terapeuticos de isoxazol. | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| DK1480961T3 (da) | Glutaminylbaserede DPIV-inhibitorer | |
| EA017405B9 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| GEP20115320B (en) | Non-nucleoside reverse transcriptase inhibitors | |
| MX2009005881A (es) | Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida. | |
| MX2009009920A (es) | Inhibidores no nucleosidos de transcriptasa inversa. | |
| CY1107956T1 (el) | Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον | |
| MY162157A (en) | Substituted indole mcl-1 inhibitors | |
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| WO2009026248A3 (en) | Hydrazide, amide, phthalimide and phthalhydrazide analogs as inhibitors of retroviral integrase | |
| MX2009007668A (es) | 1,3-dioxanos sustituidos y sus usos. | |
| MX2021015942A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| PE20081169A1 (es) | Compuestos tipo pirazol y triazol sustituidos como inhibidores de ksp | |
| EP4316504A3 (en) | Compounds | |
| EP1725536B8 (en) | Imidazoline derivatives having cb1-antagonistic activity | |
| AU2006273692A8 (en) | 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| MX2009010932A (es) | Inhibidores no nucleosidos de transcriptasa inversa. | |
| MX2009012704A (es) | Inhibidores de transcriptasa inversa de no nucleosidos. | |
| WO2007058862A3 (en) | Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
| MX2025001312A (es) | Formas cristalinas y sales de un agonista del receptor muscarinico | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors |